K36 Therapeutics
About:
K36 Therapeutics translate epigenetic modulation of oncogenic pathways into small molecule therapies.
Website: https://www.k36tx.com
Top Investors: F-Prime Capital, Bristol-Myers Squibb, Atlas Venture, Eight Roads Ventures, Nextech Invest
Description:
K36 Therapeutics translate epigenetic modulation of oncogenic pathways into small molecule therapies.
Total Funding Amount:
$100M
Estimated Revenue Range:
$1M to $10M
Headquarters Location:
Cambridge, Massachusetts, United States
Founded Date:
2021-01-01
Contact Email:
info(AT)k36tx.com
Founders:
Yang Shi
Number of Employees:
11-50
Last Funding Date:
2023-06-28
IPO Status:
Private
Industries:
© 2025 bioDAO.ai